-
Daiichi Sankyo Opens New Affiliate for Oncology in GreeceDaiichi Sankyo2024-07-15 09:32:07Daiichi Sankyo Opens New Affiliate for Oncology in Greece
-
New subgroup analyses of CLEAR Outcomes data showed bempedoic acid reduced the risk of major adverse cardiovascular events across various patient groupsDaiichi Sankyo2024-08-06 16:38:16New subgroup analyses of CLEAR Outcomes data showed bempedoic acid reduced the risk of major adverse
-
Multidisciplinary Think Tank proposes recommendations to improve holistic cardiovascular care in EuropeDaiichi Sankyo2024-08-06 16:38:29Multidisciplinary Think Tank proposes recommendations to improve holistic cardiovascular care in Europe
-
First-in-class cholesterol-lowering treatment NILEMDO®▼ and its combination with ezetimibe, NUSTENDI®▼, approved in Europe to lower LDL cholesterol and reduce cardiovascular riskDaiichi Sankyo2024-08-06 16:38:40First-in-class cholesterol-lowering treatment NILEMDO®▼ and its combination with ezetimibe, NUSTENDI®▼,
-
CHMP issues positive opinions for both bempedoic acid and the bempedoic acid / ezetimibe fixed-dose combination tablet as treatments for hypercholesterolaemia and significantly reducing cardiovascular eventsDaiichi Sankyo2024-03-25 09:37:57CHMP issues positive opinions for both bempedoic acid and the bempedoic acid / ezetimibe fixed-dose
-
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast CancerDaiichi Sankyo2024-03-25 10:05:10Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small
-
Daiichi Sankyo investiert ca. eine Milliarde Euro in Deutschland: Standort Pfaffenhofen (Bayern) wird zu internationalem Innovationszentrum ausgebautDaiichi Sankyo2024-02-15 11:44:37Daiichi Sankyo investiert ca. eine Milliarde Euro in Deutschland: Standort Pfaffenhofen (Bayern) wird zu
-
Declaration of Principle Supply Chain Due Diligence ActDaiichi Sankyo2024-01-11 10:13:05Declaration of Principle Supply Chain Due Diligence Act
-
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending LitigationDaiichi Sankyo2024-01-03 13:44:14Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including
-
VANFLYTA® Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AMLDaiichi Sankyo2023-11-09 08:10:56VANFLYTA® Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed
